<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525105</url>
  </required_header>
  <id_info>
    <org_study_id>18/II/26.10.20</org_study_id>
    <nct_id>NCT04525105</nct_id>
  </id_info>
  <brief_title>SMAD2, SMAD3 AND TGF-β GENE EXPRESSION IN URGE URINARY INCONTINENCE</brief_title>
  <official_title>ARE SMAD2, SMAD3 AND TGF-β GENE EXPRESSION VALUABLE IN THE MANAGEMENT OF THE URGE URINARY INCONTINENCE?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muğla Sıtkı Koçman University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Muğla Sıtkı Koçman University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urge urinary incontinence (UUI) is a common health problem. Changes in collagen metabolism in&#xD;
      pelvic support organs, such as uterosacral ligaments (USLs), might be responsible for the&#xD;
      complex pathophysiology of UUI. The TGF-β pathway is involved in collagen synthesis and&#xD;
      degradation. The Transforming Growth Family- β (TGF-β) superfamily has essential&#xD;
      intracellular signaling components, such as newly identified SMAD family members. We&#xD;
      evaluated the changes in the levels of TGF-β and SMAD gene and protein expression in the USL&#xD;
      of patients with concomitant pelvic organ prolapse (POP) and UUI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study included 10 patients who had been diagnosed with POP and UUI in the study group&#xD;
      and 14 asymptomatic women without complaints of POP and UUI in the control group. Biopsy&#xD;
      samples were collected from bilateral USL tissues during vaginal or abdominal hysterectomy.&#xD;
      Total RNA was extracted from USL tissue and analyzed by qPCR. The protein expression levels&#xD;
      were also analyzed with ELISA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SMAD2</measure>
    <time_frame>intraoperative</time_frame>
    <description>tissue expression and protein level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SMAD3</measure>
    <time_frame>intraoperative</time_frame>
    <description>tissue expression and protein level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TGF-ß1 mRNA Expression Levels</measure>
    <time_frame>intraoperative</time_frame>
    <description>tissue expression and protein level</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>SMAD2</condition>
  <condition>SMAD3</condition>
  <condition>TGF-β</condition>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Urge Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>wıth URGE INCONTINANCE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>not urge incontinance</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SMAD2</intervention_name>
    <description>a family of structurally related cytokines</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
    <other_name>SMAD3</other_name>
    <other_name>TGF-β1</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who had been diagnosed with POP and UUI and asymptomatic women without complaints&#xD;
        of POP and UUI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients who had been diagnosed with POP and UUI&#xD;
&#xD;
          -  asymptomatic women without complaints of POP and UUI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who have SUI,&#xD;
&#xD;
          -  a history of gynecologic malignancy,&#xD;
&#xD;
          -  endometriosis,&#xD;
&#xD;
          -  connective tissue disorders,&#xD;
&#xD;
          -  asthma,&#xD;
&#xD;
          -  previous pelvic inflammatory disease,&#xD;
&#xD;
          -  pelvic radiation anamnesis,&#xD;
&#xD;
          -  smoking,&#xD;
&#xD;
          -  previous surgery for POP or UI,&#xD;
&#xD;
          -  those on steroid therapy and hormone replacement therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>&gt; 18 years</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mugla Sıtkı Kocman University Faculty of Medicine</name>
      <address>
        <city>Mugla</city>
        <zip>48000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Muğla Sıtkı Koçman University</investigator_affiliation>
    <investigator_full_name>Melike Nur AKIN</investigator_full_name>
    <investigator_title>Dr Melike Nur Akın</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>If anyone demand the results of our study, we can share data with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

